α-synuclein Inhibitor

α-Synuclein 4554W is an inhibitor of α-Synuclein (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease.

Peucedanocoumarin III is an α-synuclein fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease.

BTA-1_b (BTA-1-CH3) is a structural analog of BTA-1 (HY-W278021). BTA-1 is an uncharged derivative of Thioflavin-T. It exhibits high affinity for Aβ fibrils and demonstrates excellent brain penetration and clearance capabilities.

Movronersen sodium is an antisense oligonucleotide targeted to α-synuclein.

Movronersen sodium scrambled negative control is the sequence scrambled negative control of Movronersen sodium.

Movronersen is an antisense oligonucleotide targeted to α-synuclein.

Crocin II (Standard) is the analytical standard of Crocin II. This product is intended for research and analytical applications. Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.

ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease.

SK-129 is a blood-brain barrier-permeable inhibitor of α-synuclein (αS) oligomers with a K_d of 221 nM. SK-129 preferentially binds to neurotoxic αS oligomers over physiological αS monomers, inhibits αS aggregation, blocks the interaction and co-aggregation of αS with tau protein, and prevents the maturation of αS-tau condensates into amyloid aggregates. SK-129 reduces ROS production, rescues dopaminergic neuron degeneration, improves motor function, restores endogenous dopamine synthesis, increases the number of Tyrosine Hydroxylase-positive neurons, prevents brain histopathological changes, alleviates neuroinflammation, and improves survival rates in relevant models. SK-129 can be used in research related to Parkinson's disease (PD) and Lewy body dementia (LBD).

Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and α-syn inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces α-syn oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.

α-synuclein-IN-16 (Compound H1) is a α-synuclein inhibitor. α-synuclein-IN-16 significantly inhibits the secondary nucleation in α-synuclein aggregation. α-synuclein-IN-16 can be used for Parkinson’s disease research.

D-520 is a potent and brain-penetrant dopamine D2/D3 agonist (D2 EC₅₀ = 4.73 nM, K_i = 41.8 nM; D3 EC₅₀ = 2.18 nM, K_i = 0.35 nM). D-520 inhibits the formation of Aβ aggregates in vitro and promotes the disaggregation of both alpha-synuclein (α-syn) and Aβ aggregates. D-520 exhibits efficacious activity in animal models of Parkinson’s disease (PD). D-520 can be used for PD and PD with dementia (PDD) research^[1][2].

Hordenine-d₆ hydrochloride (Ordenina-d₆ hydrochloride; Peyocactine-d₆ hydrochloride) is the deuterated-labeled Hordenine hydrochloride (HY-N0113B). Hordenine hydrochloride (Ordenina hydrochloride; Peyocactine hydrochloride) is a multifunctional alkaloid with oral activity and blood-brain barrier penetration. Hordenine hydrochloride inhibits LPS-induced phosphorylation of p38, JNK, ERK1/2, p65, IκB, and AKT, prevents p65 nuclear translocation, and suppresses inflammatory cytokines and mediators. Hordenine hydrochloride inhibits melanin synthesis in melanocytes and reconstructed epidermis. Hordenine hydrochloride activates the Wnt/β-catenin signaling pathway. Hordenine hydrochloride activates DRD2, acts as a D3R partial agonist, α2A-AR full agonist, and 5-HT2A-R antagonist, and inhibits SERT and DAT. Hordenine hydrochloride inhibits α-synuclein accumulation and ameliorates motor deficits in Parkinson's disease models. Hordenine hydrochloride limits alcohol intake, reduces relapse drinking behavior. Hordenine hydrochloride can be used for research on mastitis, skin pigmentation, acute lung injury, foodborne diseases, hair loss, Parkinson's disease, bacterial infections, and alcohol use disorder.

α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research..

MAAAHR is a neuroprotective agent. MAAAHR is isolated and purified from C-phycocyanin of Spirulina platensis. MAAAHR induces antioxidant gene expression through activating the Nrf2 signaling pathway. MAAAHR inhibits excessive Autophagy by reducing the expression of proteins such as α-Syn and Parkin. MAAAHR inhibits Apoptosis. MAAAHR scavenges excessive ROS, enhances SOD, CAT, and GSH-Px activities, and reduces protein carbonyl content. MAAAHR inhibits Acetylcholinesterase. MAAAHR protects zebrafish against MPTP (HY-15608)-induced dopaminergic neuronal and neurovascular loss and alleviates motor impairment. MAAAHR can be used for research on Parkinson's disease.

HUP-55 is a prolyl endopeptidase inhibitor (IC₅₀ = 5 nM). HUP-55 reduces the dimerization of α-synuclein in Neuro2a cells and induces autophagy (Autophagy) in HEK293 cells. It also decreases the increase in reactive oxygen species (ROS) production induced by hydrogen peroxide in SH-SY5Y cells at a concentration of 10 μM. In a mouse Parkinson’s disease model, HUP-55 (10 mg/kg) improves motor function (reduces the use frequency of the impaired paw) and decreases the levels of harmful oligomers of α-synuclein in the striatum caused by overexpression of α-synuclein.

NPT100-18A is an αSyn oligomerization inhibitor. NPT10018A rescues cleaved caspase-3 levels to control levels. NPT10018A attenuates mitochondrial oxidative stress probe levels in a compartment-specific manner and, at higher concentrations, increases ATP signals. NPT100-18A can be used for the study of Parkinson’s disease (PD).

α-Synuclein inhibitor 8 is an active inhibitor of α-Synuclein with an IC₅₀ value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity.

α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.70 μM and inhibition ratio at 30 μM of 94.4%.

D-Trp-Aib is a dipeptide and amyloid-β inhibitor with a K_d of 29.6 nM. D-Trp-Aib triggers formation of non-toxic, non-β-sheet, amorphous amyloid β clusters from misfolded amyloid β monomers and toxic amyloid β oligomers, and reduces toxic amyloid β_1-42 deposits. D-Trp-Aib inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin. D-Trp-Aib can be used for the research of Alzheimer's disease.